Clozapine and incidence of myocarditis and sudden death – Long term Australian experience

International Journal of Cardiology

Volumn 238, Issue , 2017, Pages 136-139

  Khan, Arshad A ^a   Ashraf, Asma ^a   Baker, David ^a   Al Omary, Mohammed S ^a,b   Savage, Lindsay ^a   Ekmejian, Avedis ^a   Singh, Rajinder Singh Harjit ^a   Brienesse, Stephen ^a   Majeed, Tazeen ^b   Gordon, Tracy ^a   Drinkwater, Vincent ^a   Collins, Nicholas J ^a,b  

^a JOHN HUNTER HOSPITAL   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Clozapine; Myocarditis; Sudden death

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TROPONIN I; NEUROLEPTIC AGENT;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; AUSTRALIAN; CARDIOTOXICITY; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE BIOPSY; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HOSPITALIZATION; HUMAN; HUMAN TISSUE; KRUSKAL WALLIS TEST; MAJOR CLINICAL STUDY; MALE; MYOCARDITIS; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY; QRS COMPLEX; QTC INTERVAL; SCHIZOPHRENIA; SUDDEN DEATH; AGED; AUSTRALIA; CHEMICALLY INDUCED; DRUG EFFECTS; INCIDENCE; MIDDLE AGED; SUDDEN CARDIAC DEATH; TIME FACTOR; TRENDS;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; AUSTRALIA; CLOZAPINE; COHORT STUDIES; DEATH, SUDDEN, CARDIAC; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDITIS; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 85016011337     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2017.03.013     Document Type: Article

References (18)

1. Voruganti, L., Cortese, L., Oyewumi, L., Cernovsky, Z., Zirul, S., Awad, A., Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr. Res. 43:2 (2000), 135–145.
2. Lewis, S.W., Barnes, T.R., Davies, L., et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr. Bull. 32:4 (2006), 715–723.
3. Hennen, J., Baldessarini, R.J., Suicidal risk during treatment with clozapine: a meta-analysis. Schizophr. Res. 73:2 (2005), 139–145.
4. Walker, A.M., Lanza, L.L., Arellano, F., Rothman, K.J., Mortality in current and former users of clozapine. Epidemiology 8 (1997), 671–677.
5. Wheeler, A., Humberstone, V., Robinson, G., Outcomes for schizophrenia patients with clozapine treatment: how good does it get?. J. Psychopharmacol. 23:8 (2009), 957–965.
6. Ronaldson, K.J., Fitzgerald, P.B., Taylor, A.J., McNeil, J.J., Observations from 8 cases of clozapine rechallenge after development of myocarditis. J. Clin. Psychiatry 73:2 (2012), 1,252–1,254.
7. Chang, C.K., Hayes, R.D., Broadbent, M., et al. All-cause mortality among people with serious mental illness (SMI), substance use disorders, and depressive disorders in southeast London: a cohort study. BMC Psychiatry, 10(1), 2010, 77.
8. Hoang, U., Stewart, R., Goldacre, M.J., Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999–2006. BMJ, 343, 2011, d5422.
9. Chang, C.K., Hayes, R.D., Perera, G., et al. Life expectancy at birth for people with serious mental illness and other major disorders from a secondary mental health care case register in London. PLoS One, 6(5), 2011, e19590.
10. Hayes, R.D., Chang, C.K., Fernandes, A.C., et al. Functional status and all-cause mortality in serious mental illness. PLoS One, 7(9), 2012, e44613.
11. Osborn, D.P., Nazareth, I., King, M.B., Physical activity, dietary habits and coronary heart disease risk factor knowledge amongst people with severe mental illness. Soc. Psychiatry Psychiatr. Epidemiol. 42:10 (2007), 787–793.
12. Cullen, B.A., McGinty, E.E., Zhang, Y., Steinwachs, D.M., Guallar, E., Daumit, G.L., Guideline-concordant antipsychotic use and mortality in schizophrenia. Schizophr. Bull. 39:5 (2013), 1159–1168.
13. Tiihonen, J., Lönnqvist, J., Wahlbeck, K., et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374:9690 (2009), 620–627.
14. Trudeau, M.C., Warmke, J.W., Ganetzky, B., Robertson, G.A., HERG, a human inward rectifier in the voltage-gated potassium channel family. Science, 269(5220), 1995, 92.
15. Reilly, J., Ayis, S., Ferrier, I., Jones, S., Thomas, S., QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 355:9209 (2000), 1048–1052.
16. Ray, W.A., Chung, C.P., Murray, K.T., Hall, K., Stein, C.M., Atypical antipsychotic drugs and the risk of sudden cardiac death. N. Engl. J. Med. 360:3 (2009), 225–235.
17. Chow, V., Yeoh, T., Ng, A., et al. Asymptomatic left ventricular dysfunction with long-term clozapine treatment for schizophrenia: a multicentre cross-sectional cohort study. Open Heart, 1(1), 2014, e000030.
18. Rostagno, C., Domenichetti, S., Pastorelli, F., Gensini, G.F., Usefulness of NT-pro-BNP and echocardiography in the diagnosis of subclinical clozapine-related cardiotoxicity. J. Clin. Psychopharmacol. 31:6 (2011), 712–716.